EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study

M Gabriela Cabanilla iD, Michael L Bernauer, Liana M Atallah, Matthew J Briski, Jason Koury, Cecilia M Thompson, Chelsea N Rodriguez iD, Bernadette Jakeman, Thomas F Byrd

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0304103 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von M Gabriela Cabanilla und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United St…. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Ceftaroline, Bacteremia, Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methicillin-resistant Staphylococcus aureus (MRSA) is associated with high mortality rates. Despite antibiotic therapy, persistent bacteremia is challenging to treat. Combination therapy with ceftaroline has emerged as a potential treatment option; however, the optimal duration and clinical implications after bacteremia clearance are unknown.

Methods

This retrospective cohort study examined patients with high-grade or persistent MRSA bacteremia who were treated with ceftaroline combination therapy at the University of New Mexico Hospital between January 2014 and June 2021. Patients were categorized into short- (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusCeftarolineBacteremiaAnti-Bacterial AgentsStaphylococcal InfectionsCephalosporinsDrug Therapy, CombinationHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment Outcome

Substanzen

CeftarolineAnti-Bacterial AgentsCephalosporins

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
  • Department of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States of America.
  • RS21, Albuquerque, New Mexico, United States of America.
  • TriCore Reference Laboratories, Albuquerque, New Mexico, United States of America.
  • Department of Pharmacy Practice and Administrative Sciences, University of New Mexico College of Pharmacy, Albuquerque, New Mexico, United States of America.

ORCID-Profile: M Gabriela Cabanilla, Chelsea N Rodriguez

Zitieren

APA

Cabanilla, M. G., Bernauer, M. L., Atallah, L. M., Briski, M. J., Koury, J., Thompson, C. M., Rodriguez, C. N., Jakeman, B., & Byrd, T. F. (2024). Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study. PLOS ONE. https://doi.org/10.1371/journal.pone.0304103

Vancouver

Cabanilla MG, Bernauer ML, Atallah LM, Briski MJ, Koury J, Thompson CM, et al. Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study. PLOS ONE. 2024. doi:10.1371/journal.pone.0304103

BibTeX
@article{Cabanilla2024,
  author = {Cabanilla, M Gabriela and Bernauer, Michael L and Atallah, Liana M and Briski, Matthew J and Koury, Jason and Thompson, Cecilia M and Rodriguez, Chelsea N and Jakeman, Bernadette and Byrd, Thomas F},
  title = {Short versus long duration of ceftaroline combination therapy and outcomes in persistent or high-grade MRSA bacteremia: A retrospective single-center study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0304103}
}
Kostenlos starten →